Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Recruiting · NCT05655949 · Registry updated 2026-04-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 2 | 2026-04-22 | NCT05655949 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beth Israel Deaconess Medical Center | 161 |
| Dana-Farber Cancer Institute | 324 |
| Sirtex Medical | 9 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |